Home >> Hot Products

Hot Products

Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.

Hot products from the professional high-purity natural products manufacturer

Cat.No.	Product Name
BCC2224	Sirtinol
Cell-permeable, selective sirtuin deacetylase inhibitor (IC₅₀ values are 38, 68 and 131 μM at SIRT2, Sir2p and SIRT1 respectively) that has no effect on HDAC1 activity. Significantly decreases growth and viability of PCa and HEK293T cells in vitro.
BCC2228	2-Methoxyestradiol (2-MeOE2)
Apoptotic, antiproliferative and antiangiogenic agent, in vitro and in vivo; acts via an estrogen receptor-independent mechanism. Induces p53-induced apoptosis via two pathways: activation of p38 and NF-κB; and activation of JNK and AP-1 leading to Bcl-2 phosphorylation. Also upregulates death receptor 5 and binds to tubulin, inhibiting its assembly.
BCC2229	IOX2(Glycine)
Potent inhibitor of HIF-1α prolyl hydroxylase-2 (PHD2) (IC₅₀ = 21 nM). Displays over 100-fold selectivity for PHD2 over factor inhibiting HIF-1 (FIH-1) and histone demethylases JMJD2A, JMJD2C, JMJD2E and JMJD3. Cell permeable.
BCC2230	GSK J4 HCl
Histone lysine demethylase (KDM) inhibitor; blocks demethylation of histone H3K27. Attenuates lipopolysaccharide (LPS)-induced proinflammatory cytokine production in primary human macrophages (IC₅₀ = 9 μM for the inhibition of TNFα release). Cell permeable. Ethyl ester derivative of GSK J1.
BCC2231	GSK J1
Potent inhibitor of the H3K27 histone demethylases JMJD3 (KDM6B) and UTX (KDM6A) (IC₅₀ values are 28 and 53 nM respectively). Also inhibits KDM5B, KDM5C and KDM5A (IC₅₀ values are 170, 550 and 6,800 nM respectively). Exhibits no activity against a panel of other histone demethylases (IC₅₀ >20 μM), and displays no significant inhibitory activity against 100 protein kinases at a concentration of 30 μM. Ethyl ester derivative also available.
BCC2233	SMI-4a
Selective, ATP-competitive Pim kinase inhibitor (IC₅₀ values are 24 and 100 nM for Pim-1 and Pim-2 respectively). Displays selectivity over a panel of ~50 other kinases tested. Exhibits cytotoxicity in PC3 prostate carcinoma cells in vitro (IC₅₀ = 17 μM).
BCC2241	Pifithrin-α (PFTα)
Inhibitor of p53; reversibly blocks p53-dependent transcriptional activation and apoptosis. Protects against neuronal death in models of stroke and neurodegenerative disorders. Active in vivo; protects mice from the side-effects of cancer therapy associated with p53 induction. Supresses self-renewal of embryonic stem cells. Also aryl hydrocarbon receptor (AHR) agonist, causes upregulation of AHR target gene CYP1A1 (EC₅₀ = 1.1 μM). Cyclic analog available.
BCC2244	Bay 11-7821(BAY 11-7082)
E2 ubiquitin (Ub) conjugating enzyme inhibitor. Inhibits the conjugation of Ub to a range of E2 enzymes. Inhibits E2 enzyme mediated IκBα phosphorylation and indirectly decreases NF-κb activity. Also reversibly activates MAPK signaling. Induces apoptosis of leukemic T cell and B-cell lymphoma cell lines.